Abstract: Huntington is the protein mutated in Huntington disease, a dominant inherited neurodegenerative disorder. Huntingtin is ubiquitously expressed throughout the body, however its role outside the central nervous system has been overlooked. This review focuses on the peripheral distribution of huntingtin. It also highlights that huntingtin has central cellular functions, the importance of which may extend beyond the nervous system. Because of the breadth of huntingtin expression and functions, mutant huntingtin undoubtedly causes peripheral disturbances and may be involved in other non neuronal pathologies.

Keywords: Huntingtin, peripheral tissues, expression pattern, huntingtin function

Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disorder [1]. The most characteristic symptoms of HD are psychiatric disorders, cognitive decline and disturbance of muscle coordination. The signs and symptoms of the disease generally emerge during mid-adulthood. The mutation causing HD is an abnormal CAG expansion in the IT15 (HTT) gene coding for the protein huntingtin (HTT) [2]. The expanded CAG repeat encodes a polyglutamine stretch near the N-terminus of the protein, and its size correlates with the time of onset of the disease: particularly large expansions are linked to juvenile forms of the disease [3]. The major histological feature of the disease is massive neuronal loss. Selective death of neurons in the striatum and cortex regions is particularly marked. Thus, in view of the neurological signs, the neuropathology and the dominant trait of HD, research on this disease has historically focused on the dominant gain of toxic function of mutant HTT in post-mitotic neurons. However, evidence is now emerging that other issues need to be considered if we are to understand the progression of HD.

**HTT EXPRESSION IS NOT RESTRICTED TO THE BRAIN**

HTT expression is ubiquitous (Table 1), as established shortly after the identification of the gene in 1993 [2]. Northern blot analyses and in situ hybridization have shown the presence of human HTT transcripts throughout the brain and also in heart, placenta, lung, liver, muscle, kidney, pancreas and testes [4, 5]. By 1995, with the development of specific antibodies, the HTT protein had been found both in the brain and also elsewhere than the central nervous system [6–8]. Since then, studies have shown that human HTT is present in several non central nervous system-derived cells [6, 7, 9–17]. Similarly, rat and mouse HTT are found at various concentrations throughout most tissues [4, 7, 8, 14, 17–22]. The wide distribution pattern of HTT is confirmed by studies analyzing HD mouse models where HTT is expressed under its own promoter. In these models, mutant HTT is observed in different peripheral tissues where it forms intranuclear inclusions [23–26].

However, a thorough and careful analysis of HTT expression is still required. Indeed, most relevant studies report the presence of the protein in lysates of whole tissues: the abundance of HTT has not been systematically evaluated in the diverse cellular subtypes...
Table 1
A summary of the literature on HTT peripheral expression

<table>
<thead>
<tr>
<th>HTT</th>
<th>Species</th>
<th>Cells, tissues</th>
<th>Method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>monocytes</td>
<td>RT-PCR</td>
<td>[9]</td>
</tr>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>lymphoblasts</td>
<td>PCR</td>
<td>[10]</td>
</tr>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>lymphoblasts</td>
<td>WB, IF</td>
<td>[6, 7, 10–15]</td>
</tr>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>primary muscle cell cultures</td>
<td>IF</td>
<td>[16]</td>
</tr>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>heart, testis, kidney, lung, liver</td>
<td>WB</td>
<td>[6, 8]</td>
</tr>
<tr>
<td>WT and mutant</td>
<td>human</td>
<td>mammary tissue, breast tumors</td>
<td>IHC</td>
<td>[22]</td>
</tr>
<tr>
<td>WT</td>
<td>human</td>
<td>heart, placenta, lung, liver, skeletal muscle, kidney, pancreas</td>
<td>Northern blot</td>
<td>[4]</td>
</tr>
<tr>
<td>WT</td>
<td>human</td>
<td>pancreas (acin. ducts, islets of Langerhans, connective tissue), testis (spermatogenesis, primary spermatocytes)</td>
<td>in situ hybridization</td>
<td>[5]</td>
</tr>
<tr>
<td>WT</td>
<td>human</td>
<td>skin fibroblasts</td>
<td>IF, WB</td>
<td>[17]</td>
</tr>
<tr>
<td>WT</td>
<td>rat</td>
<td>testis, ovary, lung, spleen, liver, heart, kidney, small intestine</td>
<td>Northern blot</td>
<td>[4, 18]</td>
</tr>
<tr>
<td>WT</td>
<td>rat</td>
<td>testis, ovary, lung, spleen, kidney</td>
<td>WB</td>
<td>[7, 14]</td>
</tr>
<tr>
<td>WT</td>
<td>mouse</td>
<td>embryonic liver, lung, kidney, heart, and adult liver, lung, placenta</td>
<td>Northern blot</td>
<td>[18, 19]</td>
</tr>
<tr>
<td>WT</td>
<td>mouse</td>
<td>embryonic liver and heart, adult testis (expression limited to mitotic cells, spermatocytes I and II)</td>
<td>in situ hybridization</td>
<td>[18]</td>
</tr>
<tr>
<td>WT</td>
<td>mouse</td>
<td>embryonic liver, hematopoietic cells, adult bone marrow</td>
<td>RT-PCR</td>
<td>[20]</td>
</tr>
<tr>
<td>WT</td>
<td>mouse</td>
<td>heart, kidney, testis, liver, lung, muscle, spleen, lymph node, hematopoietic cells, mammary cells</td>
<td>WB</td>
<td>[8, 20, 21]</td>
</tr>
<tr>
<td>WT</td>
<td>mouse</td>
<td>embryonic fibroblasts</td>
<td>IF</td>
<td>[17]</td>
</tr>
</tbody>
</table>

RT-PCR: reverse transcription-PCR; WB: western blot; IF: immunocytofluorescence; IHC: immunohistochemistry.

within peripheral tissues. A low level of HTT in a tissue sample may reflect the heterogeneity of HTT production: it may be abundant in some cellular subtypes and absent from others. Also, the precise subcellular distribution of HTT in peripheral cells is not available. We explored HTT distribution in a comprehensive array of normal human tissues using the freely available Human Protein Atlas web-based database (http://www.proteinatlas.org/ENSG00000197386, version 10.0) [27]. An analysis of HTT in several normal human tissues with two antibodies targeting different regions of HTT (MAB2166, Ab1, Chemicon and HPA026114, Ab2, Sigma-Aldrich) reveals moderate to high levels of the protein in many tissues (Fig. 1). As expected, HTT is abundant in several regions of the brain and various cell types in the central nervous system. For example, both neurons and glial cells in the cortex are stained, with higher levels of HTT in neurons (Fig. 1). HTT is also found in other cell types and tissues including: hematopoietic cells (bone marrow, white and red pulp in the spleen), glandular epithelium (fallopian tube, colon, breast, salivary gland, pancreas, and uterus), squamous epithelium (skin), macrophages and pneumocytes in the lung, seminiferous ducts in the testis and glomeruli or tubule cells in the kidney. All these tissues express moderate to high levels of HTT. One striking observation is that cells with little or no HTT are mesenchymal cells. Indeed, the antibodies do not label, or only weakly label, fibroblasts in skin, adipocytes in breast, stromal cells in uterus, myocytes and smooth muscle cells, all these cell types share mesenchymal properties. Interestingly, epithelial cells in the same tissues as these mesenchymal cells have higher levels of HTT as illustrated by the high expression observed in the ductal cells in the mammary gland and squamous epithelial cells in the skin. This distribution of HTT, present mostly in epithelial cells, is in agreement with recent studies indicating that HTT is a regulator of tissue maintenance and cell morphology. Mammary tumor cells that express mutant HTT undergo more substantial epithelial-to-mesenchymal processes than cells with the wild-type HTT [22]. This may be the result of the expression of the mutant form of HTT, or alternatively due to the downexpression of the wild-type HTT: tumors expressing the mutant HTT contain less wild-type HTT. Consistent with this, reducing HTT levels in zebrafish embryos impairs N-cadherin-mediated adhesion and leads to aberrant distribution of the tight junction protein zona occludens 1, ZO1 [28]. The mRNAs for adherence proteins are
HTT interacts with transcriptional repressors: the nuclear tumor suppressor protein 53 (p53) [47]. HTT also interacts with various organelles and structures, including clathrin-coated vesicles, endosomal and endoplasmic compartments, mitochondria, microtubules and the plasma membrane [14, 31–34].

Thus, HTT has a broad expression pattern at the histological, cellular and intracellular levels. However, this does not mean that the distribution of HTT is homogeneous in space and time. The amount of HTT differs between cell types within a tissue (see above), and HTT is expressed from early development to adulthood. The expression profile of HTT thus raises questions concerning the functions of HTT in these tissues, the relevance of these functions to tissue homeostasis, and the consequences of dysfunctions of HTT in the context of HD.

HTT FUNCTIONS

HTT has been implicated in a large range of cellular events during development and adulthood, mostly in the nervous system. HTT is required for normal embryogenesis, as knock-out mice for HTT die at an early developmental stage, embryonic day 7.5 [35–37]. In adult mice, ablation of HTT in the forebrain and in the testes leads to neurodegeneration and sterility [38]. HTT is involved in neurogenesis during both development and adulthood [39, 40]. It also participates in the control of neuronal synaptic activity [41]. How can HTT participate in such a variety of physiological processes? It is possible that the effects of HTT at the tissue level may be the consequence of a limited set of functions at the molecular level. Indeed, a common point to the physiological functions of HTT is that they may often be related to the role of HTT as a regulator of transcription and of intracellular dynamics.

HTT shuttles between the cytoplasm and the nucleus [42]. Its sequence contains two nuclear export signal sequences (NES), a karyopherin β1/β2 proline-tyrosine nuclear localization signal (NLS), and polyQ and polyP sequences that form polar zipper structures and interact with DNA [43–46]. HTT interacts with several transcription factors including the cAMP response element-binding protein (CREB binding protein, CBP) [47], the specificity protein-1 (SP1) [48], the nuclear factor-kB (NF-kB) [49] and the tumor suppressor protein 53 (p53) [47]. HTT also interacts with transcriptional repressors: the nuclear co-repressor (NCO) [50], the repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF) [51] and the transcriptional corepressor C-terminal-binding protein (CBP) [52]. Through these interactions, HTT can potentiate transcription factors and inhibit repressors (and vice versa) and thereby promote and repress gene transcription. For instance, p53 interacts with HTT [47, 53], thus blocking the transcription of p53 target genes including the multi-drug resistance gene (MDR1). The HTT-dependent p53 transcriptional regulation depends on the polyQ and polyP expansions in HTT. As p53 positively regulates the transcription of genes involved in cell cycle control, apoptosis, cellular stress response and DNA repair, the interaction of HTT with p53 may be a mechanism by which HTT regulates a wide range of cellular outcomes. In line with this idea, HTT activates the transcription of genes containing a conserved 21–23 base pair DNA Repressor element 1 sequence (RE1 also known as the neuron restrictive silencer element, NRSE) [51]. This sequence is recognized by the RE1-silencing transcription factor (REST, also known as neuronal restrictive silencing factor, NRSF), a transcriptional regulator which acts as a transcriptional silencer. HTT may thus act as a positive transcriptional regulator for these genes [51]. An example is the brain-derived neurotrophic factor (BDNF) gene, the promoter II of which contains a NRSE. Wild-type HTT promotes BDNF transcription through the sequestration of the available REST/NRSF in the cytoplasm, thereby preventing it from forming the nuclear co-repressor complex at the RE1/NRSE nuclear site.

Although HTT is present in the nucleus, the protein is mostly in the cytoplasm where it associates with vesicles and microtubules. HTT is indeed crucial for vesicular trafficking with consequences for axonal transport and endocytosis. In the same way as for its transcriptional function, the role of HTT in these trafficking and transport processes is supported by the nature of its interactors. HTT binds dynein and HAP1 directly [54], and kinesin [55] and the dynactin subunit p150Glued [56] indirectly. HTT is a facilitator of the transport of several cargoes along microtubules [33, 57, 58]. Reducing HTT levels leads to a decrease in both anterograde and retrograde transport of BDNF and its receptor TrkB [33, 59]. HTT is also required for the transport of proteins to the centrosome [39] and to the base of the cilium [60]. The action of HTT in microtubule-based transport is regulated by phosphorylations at serine 421 (S421; [61]) and serines 1181 and 1201 (S1181/S1201; [40]). In particular, phospho-rylation of HTT at S421 favors the interaction between
C. Marques Sousa and S. Humbert / Huntingtin: Here, There, Everywhere!

Fig. 1. Huntingtin expression pattern in healthy tissues. Immunohistochemistry using two antibodies directed against huntingtin (Ab1: MAB2166, Ab2: HP625114). Expression in the cortex (neurons; glandular cells; connective tissue), colon (glandular cells; lamina propria; adipocytes), fallopian tube (glandular cells; connective tissue), breast (glandular cells; adipocytes; hematopoietic cells; adipocytes; salivary gland (glandular cells; adipocytes; secretory acini; pancreas; ducts; islet of Langerhans; acini); lung (bronchus; connective tissue; alveoli); kidney (proximal tubules; distal tubules; glomerulus); heart (myocytes); uterus (glandular cells; stroma); thyroid (glandular cells); testis (seminiferous ducts; connective tissue); spleen (white pulp; red pulp) and skin (squamous epithelium; connective tissue). Scale bar corresponds to 100 μm. Images adapted from the human protein atlas website, version 11.0.
HTT and the anterograde motor kinesin-1 and as a consequence, anterograde transport. HTT thereby acts as a molecular switch determining whether transport is anterograde or retrograde [61].

Endocytosis also appears to be an HTT-mediated process. One of the first identified HTT interactors was huntingtin-interacting protein 1 (HIP1). HIP1 participates in clathrin-mediated endocytosis by supporting membrane invagination and the assembly of the clathrin coating [62–65]. Both HTT and HIP1 interact with AP-2; HTT may modulate the assembly of HIP1 with AP-2 and clathrin, localizing the complex to the membrane and regulating clathrin-coated pit formation. HTT also interacts with and activates the GTPase Rab11 involved in vesicle recycling during endocytosis [66]. HTT localizes Rab11 to the membrane and participates in the GDP-GTP exchange that activates Rab11. The early endosomal trafficking effector, Rab5 GTPase, can form a complex with HTT through HAP40, such that the HTT-HAP40-Rab5 complex associates with early endosomes [67]. Interestingly, the HAP40-HTT complex also interacts with the myosin VI linker, optineurin [68]. Thus, the involvement of HTT in endocytosis is consistent with HTT being a crucial link between the microtubule and the actin cytoskeletons. HTT in a HAP40-Optineurin-MyosinVI complex may regulate actin-dependent dynamics, whereas in complex with dynein-dynactin-kinesin it may regulate microtubule-dependent transport.

These examples illustrate how the molecular biology of HTT is complex; however, what we know is consistent with HTT functioning as a scaffold protein for molecular complexes involved in a restricted number of functions. Nevertheless, these functions may have consequences for a wide variety of physiological outcomes during both development and the maintenance of adult homeostasis. For instance, through its function as a regulator of microtubule-based dynamics, HTT influences the division of progenitors at the ventricular zone during corticogenesis [39], the maturation of newly generated neurons during adult hippocampal neurogenesis [40] and ciliogenesis in ependymal cells [60]. Clearly, the challenge for scientists is to determine when and where the HTT complexes function and their relevance to HD pathogenesis. One way to better define the expression of HTT in individual cells could be to generate mouse lines expressing the GFP reporter under the control of the HTT promoter. Alternatively, a GFP could be knocked-in at the HTT locus to express a GFP-fused HTT protein in mouse. These mouse models could then be analyzed using novel histological methods to directly acquire in three dimension entire mouse organs [69]. Such work may well lead to new insights and perspectives on HTT biology.

PHYSIOLOGICAL OUTCOME OF HTT OUTSIDE OF THE NERVOUS SYSTEM

An indirect argument that HTT also acts outside the nervous system is that HD patients present with peripheral manifestations. These symptoms of HD have been recently reviewed and include: weight loss; endocrine and metabolic dysfunctions; defects in hematopoiesis; skeletal muscle and testicular atrophy; aberrant immune cell migration; and cardiac dysfunction [70, 71]. Conversely, mutant HTT may have an effect on other pathologies, and indeed, this is the case for cancer. Two studies have showed an overall decreased risk of cancer in patients with HD [72, 73]. Although the incidence of cancer is lower among HD patients, the progression may be faster, mutant HTT being an aggravating factor once cancer is initiated [22]. The peripheral abnormalities observed in HD patients were initially thought to be the consequence of nervous system dysfunction, but it is now clear that at least some are caused directly by the expression of mutant HTT in the affected tissues. However, the details of the molecular mechanisms underlying these peripheral symptoms remain unclear. Non-neuronal tissues may be sensitive to the oxidative stress, inflammation, mitochondrial dysfunction, and abnormalities of energy metabolism and gene transcription caused by the presence of mutant HTT [70, 71]. The loss of the normal function of HTT in these tissues may also cause damage. For example, polyQ-induced abnormalities in HER2 endocytosis in breast cancer cells have consequences for their motility and metastatic behavior leading to increased tumorigenesis and metastasis in HD mice [22].

Although HTT is abundant in a number of tissues (Table 1 and Fig. 1), there have been very few investigations of the physiological relevance of HTT outside of the nervous system. In zebrafish, HTT knock-down produces symptoms of cellular iron deficiency, including decreased hemoglobin concentrations in the blood, increased erythroid and ubiquitous transferrin receptor transcript levels and exhausted maternal iron stores in the yolk [74]. The authors suggested that the underlying mechanism may be a deficiency in endocytosis, particularly of iron, thereby limiting the availability of iron resulting in deficient hemoglobin. In agreement, an earlier study in mouse described a phenotype consistent with a defect in iron transport in extraen-
Huntingtin is regulated by its phosphorylation status [40]. Furthermore, the function of HTT in adult neurodendritic arborization of newly generated neurons [87]. Hippocampal neurons, loss of HTT affects the density of neuronal differentiation. Inactivation of HTT in cortical progenitors favors their neuronal differentiation at the expense of their proliferation [39]. In mature adult hippocampal neurons, loss of HTT affects the dendritic arborization of newly generated neurons [87]. Furthermore, the function of HTT in adult neurogenesis is regulated by its phosphorylation status [40]. There is no information available about the influence of HTT on the differentiation of non neuronal tissues in mouse. Nevertheless, in mouse models of HD and cancer, expression of polyQ-HTT in mammary tumor cells changes their cell fate and makes them more prone to adopt a mesenchymal phenotype [22].

From this diverse evidence, it seems likely that HTT is a key regulator of the balance between cell differentiation, survival and death, and that the physiological outcomes differ according to the cell type and the cell context. By studying HTT outside the nervous system, we may thus learn from the similarities and differences in its functions in the various tissues in which it is expressed. This will undoubtedly change our understanding of HD.

CONCLUSION

There is an urgent need for effective treatments for HD that will either slow down or halt the progression of neuronal dysfunction and degeneration. The development of such therapies is based on a sound understanding of the etiology and pathogenesis of this disease. HD is a dominant disorder, but there is evidence that loss of the normal functions of wild-type HTT could act concomitantly and synergistically with the gain of new toxic functions of polyQ-HTT. In fact, the situation is more complex than that. Loss of function of HTT could be a dominant mechanism; this is the case for intracellular transport [33]. Furthermore, HD patients express not only one copy of the mutant huntingtin, but also half the amount of the wild-type protein. A deep knowledge of HTT biology in peripheral tissue might be used to identify biomarkers for disease progression and for readout of treatment efficacy. The HD scientific community should thus be involved in basic studies looking precisely at the spatial and temporal distribution of HTT, and describing the relevance of HTT function where and when it is expressed. Finally, deciphering how mutant HTT acts in other pathological situations like cancer and cardiovascular disease, would also help to better understand the complex biology of HTT and its mutation.

ACKNOWLEDGEMENTS

We are grateful to F. Saudou for discussions. The laboratory is funded by grants from Agence Nationale pour la Recherche (ANR), Association pour
la Recherche sur le Cancer (ARC), Fondation pour la Recherche Médicale (FRM). S.H. is a INSERM investigator. C.M.S. was supported by a Fundação para a Ciência e a Tecnologia (FCT, Portugal) doctoral fel-lowship (SFRH/BD/60728/2009).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES


